Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07818291) titled 'An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Lanyi Therapeutics Co., Ltd.
Condition:
Generalized Myasthenia Gravis (gMG)
Intervention:
Drug: EA5
Drug: EA5
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 15, 2026
Target Sample Size: 18
Countries of Recruitment:
China
To...